Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine during surgery for postoperative depression in gynecologic oncology
ChiCTR2500103944Phase 4Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) and gynecological cancer (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: HADS-D score 7 days after surgery. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)gynecological cancer
Beyond the preview
Go deeper on ChiCTR2500103944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103944.